A U.S. Food and Drug Administration (FDA) sign is seen outside the agency’s White Oak campus in Silver Spring, Md., on July 17, 2025. Issam Ahmed/AFP via Getty Images
The Food and Drug Administration recently announced new measures to prevent the import of dangerous foreign counterfeits of GLP-1 drug ingredients, which are being used to make unapproved compound drugs targeting individuals seeking weight loss medication.
On Sept. 5, the FDA announced the creation of a “green list” import alert for GLP-1 active pharmaceutical ingredients (APIs), according to a statement. Only GLP-1 APIs manufactured at facilities that the health agency has inspected or evaluated and found compliant with its rigorous standards will make the list, the FDA added.
